<table id="table8" width="75%" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<caption>Table 8           Proportion of Frequently Emerging Reverse Transcriptase Substitutions in the HIV-1 Virus of Resistance Analysis Subjects<footnote id="t8fa">Subjects who qualified for resistance analysis</footnote> Who Received Rilpivirine or Efavirenz in Combination with Emtricitabine/Tenofovir DF from Pooled Phase 3 TMC278-C209 and TMC278-C215 Trials in the Week 96 Analysis</caption>
<col align="left" valign="middle" width="36%"></col>
<col align="center" valign="middle" width="32%"></col>
<col align="center" valign="middle" width="32%"></col>
<thead>
<tr stylecode="Botrule">
<th rowspan="3" stylecode="Lrule Rrule"></th>
<th colspan="2" stylecode="Rrule">C209 and C215<br/>N=1096</th>
</tr>
<tr stylecode="Botrule">
<th align="center">Rilpivirine + FTC/TDF</th>
<th stylecode="Lrule Rrule">Efavirenz + FTC/TDF</th>
</tr>
<tr>
<th align="center">N=550</th>
<th stylecode="Lrule Rrule">N=546</th>
</tr>
</thead>
<tbody>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">
<content stylecode="bold">Subjects who Qualified for Resistance Analysis</content>
</td>
<td>14% (77/550)</td>
<td stylecode="Lrule Rrule">8% (43/546)</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">
<content stylecode="bold">Subjects with Evaluable Post-Baseline Resistance Data</content>
</td>
<td>70</td>
<td stylecode="Lrule Rrule">31</td>
</tr>
<tr stylecode="Botrule">
<td align="center" colspan="3" stylecode="Lrule Rrule">
<content stylecode="bold">Emergent NNRTI Substitutions<footnote id="t8fb">V90, L100, K101, K103, V106, V108, E138, V179, Y181, Y188, V189, G190, H221, P225, F227, and M230</footnote>
</content>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">Any</td>
<td>63% (44/70)</td>
<td stylecode="Lrule Rrule">55% (17/31)</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">V90I</td>
<td>14% (10/70)</td>
<td stylecode="Lrule Rrule">0</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">K101E/P/T/Q</td>
<td>19% (13/70)</td>
<td stylecode="Lrule Rrule">10% (3/31)</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">K103N</td>
<td>1% (1/70)</td>
<td stylecode="Lrule Rrule">39% (12/31)</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">E138K/A/Q/G</td>
<td>40% (28/70)</td>
<td stylecode="Lrule Rrule">0</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">  E138K+M184I<footnote id="t8fc">This combination of NRTI and NNRTI substitutions is a subset of those with the E138K.</footnote>
</td>
<td>30% (21/70)</td>
<td stylecode="Lrule Rrule">0</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">V179I/D</td>
<td>6% (4/70)</td>
<td stylecode="Lrule Rrule">10% (3/31)</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">Y181C/I/S</td>
<td>13% (9/70)</td>
<td stylecode="Lrule Rrule">3% (1/31)</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">V189I</td>
<td>9% (6/70)</td>
<td stylecode="Lrule Rrule">0</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">H221Y</td>
<td>10% (7/70)</td>
<td stylecode="Lrule Rrule">0</td>
</tr>
<tr stylecode="Botrule">
<td align="center" colspan="3" stylecode="Lrule Rrule">
<content stylecode="bold">Emergent NRTI Substitutions<footnote id="t8fd">A62V, K65R/N, D67N/G, K70E, L74I, Y115F, M184V/I, L210F, K219E/R</footnote>
</content>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">Any</td>
<td stylecode="Rrule">63% (44/70)</td>
<td stylecode="Rrule">32% (10/31)</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">M184I/V</td>
<td stylecode="Rrule">59% (41/70)</td>
<td stylecode="Rrule">26% (8/31)</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">K65R/N</td>
<td stylecode="Rrule">11% (8/70)</td>
<td stylecode="Rrule">6% (2/31)</td>
</tr>
<tr>
<td stylecode="Lrule Rrule">A62V, D67N/G, K70E, Y115F, or K219E/R<footnote id="t8fe">These substitutions emerged in addition to the primary substitutions M184V/I or K65R; A62V (n=2), D67N/G (n=3), K70E (n=4), Y115F (n=2), K219E/R (n=8) in rilpivirine resistance analysis subjects.</footnote>
</td>
<td stylecode="Rrule">20% (14/70)</td>
<td stylecode="Rrule">3% (1/31)</td>
</tr>
</tbody>
</table>